Maxim Pharmaceuticals Inc., of San Diego, said it received U.S. Patent No. 6,080,395 titled "Method and Composition for Topical Treatment of Damaged Tissue Using Histamine as Active Ingredient." It covers the pharmaceutical formulation underlying the company's MaxDerm technology.
MetaPhore Pharmaceuticals Inc., of St. Louis, said it received U.S. Patent No. 6,180,620. It covers the use of a new class of superoxide dismutase enzyme mimetic drugs for the alleviation of acute and chronic pain.
Micrologix Biotech Inc., of Vancouver, British Columbia, said it received U.S. Patent Nos. 6,180,640 and 6,191,254. They cover compositions of 46 novel peptides and their chemical derivatives designed for unique activity against bacteria and fungi.
Millennium Pharmaceuticals Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,194,556. It covers all uses of the ACE2 gene for the development of therapeutic and predictive medicine products.
MPB Cologne GmbH, of Cologne, Germany, said it received U.S. Patent No. 6,194,201. It covers an anaerobic gene expression system for recombinant proteins in plants.
Research Corporation Technologies Inc., of Tuscon, Ariz., said it received U.S. Patent No. 6,187,307. It covers vaccine technology that triggers a strong immune response against cancer.
Roche Molecular Systems, of Pleasanton, Calif., said it received U.S. Patent No. 6,171,785. It covers methods of monitoring nucleic acid amplification reactions.
Transkaryotic Therapies Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,200,563 titled "Synthetic Mammalian Sulphamidase and Genetic Sequences Encoding Same." It covers the gene and cDNA for sulphamidase.